Login / Signup

Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19.

Dingzhong LiJianbing HuDian LiWeijun YangShuang-Feng YinRenhua Qiu
Published in: Topics in current chemistry (Cham) (2021)
COVID-19 has broken out rapidly in nearly all countries worldwide, and has blossomed into a pandemic. Since the beginning of the spread of COVID-19, many scientists have been cooperating to study a vast array of old drugs and new clinical trial drugs to discover potent drugs with anti-COVID-19 activity, including antiviral drugs, antimalarial drugs, immunosuppressants, Chinese medicines, Mpro inhibitors, JAK inhibitors, etc. The most commonly used drugs are antiviral compounds, antimalarial drugs and JAK inhibitors. In this review, we summarize mainly the antimalarial drugs chloroquine and hydroxychloroquine, the antiviral drugs Favipiravir and Remdesivir, and JAK inhibitor Ruxolitinib, discussing their biological activities, clinical trials and synthesis progress.
Keyphrases
  • clinical trial
  • coronavirus disease
  • sars cov
  • systematic review
  • randomized controlled trial
  • open label
  • high throughput
  • respiratory syndrome coronavirus
  • double blind
  • phase iii
  • high density